This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dumans, A. T.
Right arrow Articles by Tanuri, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dumans, A. T.
Right arrow Articles by Tanuri, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2002, p. 3075-3079, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.3075-3079.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Prevalence of Protease and Reverse Transcriptase Drug Resistance Mutations over Time in Drug-Naïve Human Immunodeficiency Virus Type 1-Positive Individuals in Rio de Janeiro, Brazil

Ana T. Dumans,1 Marcelo A. Soares,2 Danuta Pieniazek,3 Marcia L. Kalish,3 Veronique De Vroey,4 Kurt Hertogs,4 and Amilcar Tanuri2*

Unidade de Genetica, Departamento de Ciencias Morfologicas, Instituto Biomedico, Universidade do Rio de Janeiro,1 Laboratório de Virologia Molecular, Departamento de Genética, Universidade Federal do Rio de Janeiro, Cidade Universitária—Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil,2 HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333 ,3 Tibotec-VIRCO NV, B-2800 Mechelen, Belgium4

Received 25 January 2002/ Returned for modification 23 April 2002/ Accepted 13 May 2002


arrow
ABSTRACT
 
The prevalence of mutations that confer resistance to protease inhibitors and to nucleoside and nonnucleoside reverse transcriptase inhibitors in 49 blood samples from drug-naïve human immunodeficiency virus type 1-infected blood donors living in Rio de Janeiro state, Brazil, in 1998 was evaluated genotypically and phenotypically.


arrow
TEXT
 
The new generation of drugs targeting the reverse transcriptase (RT) and protease (PR) genes of the pol region of human immunodeficiency virus type 1 (HIV-1), such as nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs), has revolutionized treatment of infected individuals (11, 18). However, not all patients respond to highly active antiretroviral treatment (HAART), and many develop drug resistance, one of the most serious obstacles to sustained suppression of HIV-1 (16, 21, 28) The emergence of amino acid mutations associated with resistance to RTIs and PIs has been extensively characterized (14, 23), and these substitutions can be classified into primary and secondary mutations. Primary mutations lead to a severalfold decrease in sensitivity to one or more antiretroviral (ARV) drugs (14, 23). Secondary mutations may not result in a significant decrease in drug sensitivity but are associated with restoration of the original viral fitness in the presence of existing inhibitors (14, 23).

The transmission and dissemination of drug-resistant strains have major public health implications, including disrupting the efficiency of established ARV treatment for HIV-1-infected patients and of prophylaxis against both accidental exposures and perinatal HIV-1 transmission. Prevalences of primary resistance mutations for any drug observed among recent seroconverters range from 5 to 11% in Switzerland (32; S. Yerly, E. Race, S. Vora, P. Rizzardi, J. P. Chave, M. Flepp, P. Vernazza, A. Telenti, M. Battegay, A. L. Veuthey, B. Hirschel, L. Perrin, and the Swiss HIV Cohort Study, Program Abstr. 8th Conf. Retroviruses Opportunistic Infections, abstr. 754, 2001), 4 to 17% in France (9, 24; M. L. Chaix, M. Harzic, B. Masquelier, I. Pellegrin, L. Meyer, D. Costagliola, C. Rouzioux, and F. Brun-Vezinet, Program Abstr. 8th Conf. Retroviruses Opportunistic Infections, abstr. 755, 2001), 13% in Germany (10), 14% in the United Kingdom (27), 2 to 26% in North America [1, 2, 5, 17, 22; S. J. Little, S. Holte, and J. P. Routy, abstract from 5th Int. Workshop HIV Drug Resist. Treatment Strategies, 4 to 8 June 2001, Scottsdale, Ariz. Antivir. Ther. 6(Suppl. 1):21, 2001], and 23 to 26% in Spain (4).

Information on PI- and RTI-associated mutations in HIV-1-infected drug-naïve individuals in Brazil is limited to specimens collected before 1996, when free access to HAART was established for AIDS patients by the Brazilian Ministry of Health (3, 26). These specimens have shown a low prevalence of mutations related to NRTIs, NNRTIs, and PIs. In this paper, we describe the genetic diversity of HIV-1 PR and RT sequences and the prevalence of mutations linked to PI and RTI resistance in treatment-naïve HIV-1-infected blood donors living in the state of Rio de Janeiro, Brazil, in 1998.

Of the 18,667 blood units collected from January through December 1998 at blood banks distributed throughout the state of Rio de Janeiro, 56 were rejected based on their HIV-1 positivity by enzyme immunoassay (Prism HIV-1/HIV-2 [Abbott, North Chicago, Ill.] and Vironostika HIV Uni-Form plus O [Organon Teknika BV, Boxtel, The Netherlands]). After confirmation by Western blot analysis, the viral RNA was isolated from plasma, and PR and RT genes were RT-PCR amplified and sequenced as previously described (26). This study was approved by the Brazilian Ethics Committee (CONEP) as an anonymous unlinked study.

Phylogenetic analysis was performed using the neighbor-joining method as previously described (25). Of 44 samples positive for both PR and RT sequences, 40 had concordant subtype assignments in these regions, including 39 (89%) subtype-B specimens and 1 (2%) subtype-C specimen (Table 1). The remaining four samples revealed discordant subtypes for the PR and RT regions, which may represent recombinant viruses. Finally, of the five specimens with HIV-1 subtype assignment for only one viral region, two PR and two RT sequences were of subtype B and one RT sequence was of subtype F. These results indicate that subtype distributions in our sampling reflect the proportions previously observed in Brazil (7, 25, 29).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Presence of PR and RT inhibitor-associated mutations in subtype-B and non-B Brazilian HIV-1 strains collected in 1998

To examine the frequency of primary (D30N, M46I, G48V, I50V, V82A, -F, or T [V82A/F/T], I84V, and L90 M) and secondary (L10I/R/V, K20M/R, L24I, V32I, L33F, M36I, M46I/L, I47V, I54L/M/V, L63P, A71V/T, G73S, V77I, V82I, and N88D) PI-associated substitutions within the PR region, we analyzed these 20 amino acid sites, which are associated in vivo with resistance in HIV-1 subtype B to PIs approved by the U.S. Food and Drug Administration (FDA) (14, 23). This analysis revealed a lack of primary substitutions in 46 PR sequences. However, secondary mutations were found in 39 (85%) of the 46 viral sequences at six positions. L63P was the most common secondary substitution (54%; 25 of 46), followed by V77I (26%; 12 of 46), M36I (20%; 9 of 46), A71V/T (15%; 7 of 46), V82I (6%; 3 of 46), and L10I/V (4%; 2 of 46). Single amino acid mutations were identified in 23 (50%) of the 46 PR sequences, whereas 34% of sequences harbored dual (30%; 14 of 46), triple (2%; 1 of 46) and quadruple (2%) PI-associated substitutions (Table 1).

To search for changes over time in the PI-associated mutations among the subtype-B infections in Brazil, PI-associated substitutions found in 41 PR sequences collected in 1998 were compared with those found in 38 sequences collected from drug-naïve individuals in 1987 to 1994 (19, 20, 26) (Fig. 1). There were no primary PI-associated mutations in PR sequences in either collection, and PI secondary mutational patterns were similar in the two sets. However, the frequency of isolates harboring PI-associated secondary resistance mutations was higher (0.025 < P < 0.05 by a one-tailed {chi}2 test) in the 1998 data set (85%) than in the 1987-to-1994 collection (66%). This finding possibly reflects a natural evolution of the PR gene over time rather than selection of HIV-1 strains harboring PI-associated substitutions resulting from PI treatment in Brazil.



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 1. Percentages of PR subtype-B sequences with PI-associated secondary amino acid mutations at two different time points. The number of sequences with the indicated mutation is given inside or directly above each bar. Statistical significances of the differences (by a one-tailed Fisher or {chi}2 test) are given above the bars. Total*, total numbers of sequences with at least one mutation.

The results presented in Table 1 indicated that none of the 47 RT sequences from the 1998 collection harbored primary mutations associated with resistance to FDA-approved NRTIs (14, 23) and only one had the secondary mutation V118I (2%; 1 of 47).

Analysis of FDA-approved NNRTI-associated mutations indicated that neither primary nor secondary substitutions (14, 23) were present in 47 RT sequences analyzed.

Our findings are in agreement with the low proportion of drug-naïve subjects infected with viruses harboring primary drug-resistant mutations in Venezuela and Argentina (8, 15) but in contrast with reports of the presence of HIV-1 strains carrying primary mutations in drug-naïve individuals in North America [1, 2, 5, 22, 31; Little et al., Antivir. Ther. 6(Suppl. 1):21, 2001] and Europe (4, 10, 24, 27, 32; Chaix et al., Program Abstr. 8th Conf. Retroviruses Opportunistic Infections, abstr. 755, 2001; Yerly et al., Program Abstr. 8th Conf. Retroviruses Opportunistic Infections, abstr. 754, 2001) who are infected with subtype-B viruses. A few factors may contribute to these differences, such as the length of time under drug selective pressures and the time period between primary infection and sampling.

In addition to specific mutations known to contribute to RTI resistance, a few unusual changes were observed in RT sequences at both the NRTI resistance-associated sites (E44G [6.4%], K70I [2.2%], V75L [2.2%], Q151K [2.2%], T215P/S [8.5%], and K219P/R/T [8.5%]) and the NNRTI resistance-associated positions (A98S [4.2%] and V106/I/L [13%]) (Table 1). Of note, recent data indicate that the T215S substitution, which was found in two of our RT sequences, is responsible for a more-rapid emergence of zidovudine (AZT) resistance in vitro, and it is speculated that this selection could also take place in vivo (J. G. Garcia-Lerma, S. Nidtha, K. Blumoff, H. Weinstock, and W. Heneine, Program Abstr. 5th Int. Workshop HIV Drug Resistance Treatment Strategies, abstr. 21 and 22, 2001).

Sixteen isolates that represented distinct phylogenetic subtypes and a variety of genotypic PI- and RTI-associated mutation patterns were selected for in vitro evaluation of susceptibility to the PIs (saquinavir [SQV], ritonavir [RTV], indinavir [IDV], nelfinavir [NFV], and amprenavir [APV]), NRTIs (AZT, lamivudine [3TC], didanosine [ddI], zalcitibine [ddC], stavudine [d4T], and abacavir [ABV]), and NNRTIs (nevirapine [NVP], delavirdine [DLV], and efavirenz [EFV]) by using VIRCO's Antivirogram assay (13). This phenotypic analysis revealed moderate resistance to NFV in only one strain (98BRVM15), which harbored quadruple PI-associated secondary mutations: 36I 63P 71V 77I. Three strains (98BRVM15, 98BRVM16, and 98BRVM85) revealed moderate resistance (4.0- to 6.5-fold) to ddI. Finally, strain 98BRVM58 showed levels of resistance above the biological cutoff value for NVP (8.0-fold) (Table 2). The levels of resistance above cutoff values for ddI and NVP observed in these samples could not be easily explained by the respective viral genotypes, which lacked primary resistance mutations. It is likely that mutations L283I, Y318F, and P236L (codons that were outside the RT fragment analyzed in this study), in combination with other, as yet unidentified NNRTI mutations, are responsible for moderate resistance. For example, the dual mutations I135T L283I were recently found to be associated with intermediate resistance to NVP and DLV (6). Our study showed that isolate 98BMVM58, which has shown resistance to NVP, had the I135T substitution. Also, it is possible that the presence of leucine instead of valine at codon 106 could contribute to the NVP resistance of this strain (Table 2). Observed discrepancies between genotype and phenotype, especially with regard to intermediate resistance to NNRTIs, have been reported previously (1, 17, 30, 31).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Phenotypic and genotypic profiles of selected samples

This study provides the most comprehensive evaluation to date of both the genetic diversity and the PR and RT drug-resistant patterns in treatment-naïve HIV-1-infected individuals after the introduction of free access to HAART in Brazil in 1996. Our findings showing a lack of resistant strains circulating in drug-naïve subjects do not support the need for genotyping before ARV therapy initiation.

Nucleotide sequence accession numbers. The nucleotide sequences of the HIV-1 PR and RT genes sequenced in this study have been assigned GenBank accession numbers AF413811 to AF413912.


arrow
ACKNOWLEDGMENTS
 
This work was supported by CAPES, CNPq, FAPERJ, and Fogarty International Center/AIDS International Training and Research Programs.

We express our gratitude to Warren D. Johnson, Jr., for encouragement and support.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Laboratório de Virologia Molecular, Departamento de Genética, Universidade Federal do Rio de Janeiro, CCS—Bl. A, sala A2-121, Cidade Universitária—Ilha do Fundão, Rio de Janeiro RJ 21944-970, Brazil. Phone: 55-21-2562-6385. Fax: 55-21-2562-6397. E-mail: atanuri{at}biologia.ufrj.br. Back


arrow
REFERENCES
 
    1
  1. Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.[Abstract/Free Full Text]
    2. 2
  2. Brenner, B., M. A. Wainberg, H. Salomon, D. Rouleau, A. Dascal, B. Spira, R. P. Sekaly, B. Conway, and J. P. Routy. 2000. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Int. J. Antimicrob. Agents 16:429-434.[CrossRef][Medline]
    3. 3
  3. Brindeiro, R., B. Vanderborght, E. Caride, L. Correa, R. M. Oravec, O. Berro, L. Stuyver, and A. Tanuri. 1999. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals. Antimicrob. Agents Chemother. 43:1674-1680.[Abstract/Free Full Text]
    4. 4
  4. Briones, C., M. Perez-Olmeda, C. Rodriguez, J. Romero, K. Hertogs, and V. Soriano. 2001. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J. Acquir. Immune Defic. Syndr. 26:145-150.
    5. 5
  5. Brodine, S. K., R. A. Shaffer, M. J. Starkey, S. A. Tasker, J. L. Gilcrest, M. K. Louder, A. Barille, T. C. VanCott, M. T. Vahey, F. E. McCutchan, D. L. Birx, D. D. Richman, and J. R. Mascola. 1999. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann. Intern. Med. 131:502-506.[Abstract/Free Full Text]
    6. 6
  6. Brown, A. J. L., H. M. Precious, J. M. Whitcomb, J. K. Wong, M. Quigg, W. Huang, E. S. Daar, R. T. D'Aquila, P. H. Keiser, E. Connik, N. S. Hellmann, C. J. Petropoulos, D. D. Richman, and S. J. Little. 2000. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J. Virol. 74:10269-10273.[Abstract/Free Full Text]
    7. 7
  7. Couto-Fernandez, J. C., M. G. Morgado, V. Bongertz, A. Tanuri, T. Andrade, C. Brites, and B. Galvao-Castro. 1999. HIV-1 subtyping in Salvador, Bahia, Brazil: a city with African sociodemographic characteristics. J. Acquir. Immune Defic. Syndr. 22:288-293.
    8. 8
  8. Delgado, E., M. Leon-Ponte, M. L. Villahermosa, M. T. Cuevas, L. Deibis, G. Echeverria, M. M. Thomson, L. Perez-Alvarez, S. Osmanov, and R. Najera. 2001. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study. AIDS Res. Hum. Retrovir. 17:753-758.[CrossRef][Medline]
    9. 9
  9. Descamps, D., V. Calvez, J. Izopet, C. Buffet-Janvresse, A. Schmuck, P. Colson, A. Ruffault, A. Maillard, B. Masquelier, J. Cottalorda, M Harzic, F. Brun-Vezinet, D. Costagliola, and The ANRS Antiretroviral Resistance Study Group. 2001. Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study. AIDS 15:1777-1782.[CrossRef][Medline]
    10. 10
  10. Duwe, S., M. Brunn, D. Altman, O. Hamouda, B. Schmidt, H. Walter, G. Pauli, and C. Kucherer. 2001. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naïve patients from the German seroconverter study. J. Acquir. Immune Defic. Syndr. 26:266-273.
    11. 11
  11. Hammer, S. M., D. A. Katzenstein, M. D. Hughes, H. Gundacker, R. T. Schooley, R. H. Haubrich, W. K. Henry, M. M. Lederman, J. P. Phair, M. Niu, M. S. Hirsch, and T. C. Merigan. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N. Engl. J. Med. 335:1081-1090.[Abstract/Free Full Text]
    12. 12
  12. Harrigan, P. R., J. S. G. Montaner, S. A. Wegner, W. Verbiest; V. Miller, R. Wood, and B. A. Larder. 2001. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 15:1671-1677.[CrossRef][Medline]
    13. 13
  13. Hertogs, K., M. P. De Bethune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.[Abstract/Free Full Text]
    14. 14
  14. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 283:2417-2426.[Abstract/Free Full Text]
    15. 15
  15. Kijak, G. H., S. E. Pampuro, M. M. Avila, C. Zala, P. Cahn, M. A. Wainberg, and H. Salomon. 2001. Resistance profiles to antiretroviral drugs in HIV-1 drug-naïve patients in Argentina. Antivir. Ther. 6:71-77.[Medline]
    16. 16
  16. Ledergerber, B., M. Egger, M. Opravil, A. Telenti, B. Hirschel, M. Battegay, P. Vernazza, P. Sudre, M. Flepp, H. Furrer, P. Francioli, R. Weber, and the Swiss HIV Cohort Study. 1999. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 353:863-868.[CrossRef][Medline]
    17. 17
  17. Little, S. J., E. S. Daar, R. T. D'Aquila, P. H. Keiser, E. Connick, J. M. Whitcomb, N. S. Hellman, C. J. Petropoulos, L. Sutton, J. A. Pitt, E. S. Rosenberg, R. A. Koup, B. D. Walker, and D. D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.[Abstract/Free Full Text]
    18. 18
  18. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.[Abstract/Free Full Text]
    19. 19
  19. Potts, K. E., M. L. Kalish, T. Lott, G. Orloff, C. C. Luo, M. A. Bernard, C. B. Alves, R. Badaro, J. Suleiman, O. Ferreira, G. Schochetman, W. D. Johnson, Jr., C. Y. Ou, J. L. Ho, and the Brazilian Collaborative AIDS Research Group. 1993. Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil. AIDS 7:1191-1197.[Medline]
    20. 20
  20. Ramos, A., A. Tanuri, M. Schechter, M. A. Rayfield, D. J. Hu, M. C. Cabral, C. I. Bandea, J. Baggs, and D. Pieniazek. 1999. Dual and recombinant infections: an integral part of the HIV-1 epidemic in Brazil. Emerg. Infect. Dis. 5:65-74.[Medline]
    21. 21
  21. Ross, L., M. Johnson, R. DeMasi, Q. Liao, N. Graham, M. Shaefer, and M. S. Clair. 2000. Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia. AIDS 14:813-819.[CrossRef][Medline]
    22. 22
  22. Salomon, H., M. A. Wainberg, B. Brenner, Y. Quan, D. Rouleau, P. Cote, R. LeBlanc, E. Lefebvre, B. Spira, C. Tsoukas, R. P. Sekaly, B. Conway, D. Mayers, and J. P. Routy. 2000. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 14:F17-F23.[CrossRef][Medline]
    23. 23
  23. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antivir. News 5:65-91.
    24. 24
  24. Tamalet, C., C. Pasquier, N. Yahi, P. Colson, I. P. Martin, G. Lepeu, H. Gallais, P. Massip, J. Puel, and J. Izopet. 2000. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J. Med. Virol. 61:181-186.[CrossRef][Medline]
    25. 25
  25. Tanuri, A., P. Swanson, S. Devare, O. J. Berro, A. Savedra, L. J. Costa, J. G. Telles, R. Brindeiro, C. Schable, D. Pieniazek, and M. Rayfield. 1999. HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20:60-66.[Medline]
    26. 26
  26. Tanuri, A., A. C. P. Vicente, K. Otsuki, C. A. Ramos, O. C. Ferreira, Jr., M. Schechter, L. M. Janini, D. Pieniazek, and M. A. Rayfield. 1999. Genetic variation and susceptibilities to protease inhibitors among subtypes B and F isolates in Brazil. Antimicrob. Agents Chemother. 43:253-258.[Abstract/Free Full Text]
    27. 27
  27. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. 2001. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 322:1087-1088.[Abstract/Free Full Text]
    28. 28
  28. Vella, S., and L. Palmisano. 2000. Antiviral therapy: state of the HAART. Antivir. Res. 45:1-7.[CrossRef][Medline]
    29. 29
  29. Vicente, A. C. P., K. Otsunik, N. B. Silva, M. C. Castilho, F. S. Barros, D. Pieniazek, D. Hu, M. A. Rayfield, G. Bretas, and A. Tanuri. 2000. The HIV epidemic in the Amazon Basin is driven by prototypic and recombinant HIV-1 subtypes B and F. J. Acquir. Immune Defic. Syndr. 23:327-331.
    30. 30
  30. Wegner, S. A., S. K. Brodine, J. R. Mascola, S. A. Tasker, R. A. Shaffer, M. J. Starkey, A. Barile, G. J. Martin, N. Aronson, W. W. Emmons, K. Stephan, S. Bloor, J. Vingerhoets, K. Hertogs, and B. Larder. 2000. Prevalence of genotypic and phenotypic resistance to antiretroviral drugs in a cohort of therapy-naïve HIV-1-infected US military personnel. AIDS 14:1009-1015.[CrossRef][Medline]
    31. 31
  31. Weinstock, H., R. Respess, W. Heneine, C. J. Petropoulos, N. S. Hellmann, C. C. Luo, C. P. Pau, T. Woods, M. Gwinn, and J. Kaplan. 2000. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J. Infect. Dis. 182:330-333.[CrossRef][Medline]
    32. 32
  32. Yerly, S., L. Kaiser, E. Race, J. P. Bru, F. Clavel, and L. Perrin. 1999. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354:729-733.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, September 2002, p. 3075-3079, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.3075-3079.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Taiwo, B. O., Murphy, R. (2007). Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings. J Int Assoc Physicians AIDS Care (Chic Ill) 6: 188-197 [Abstract]  
  • Hazen, R., Harvey, R., Ferris, R., Craig, C., Yates, P., Griffin, P., Miller, J., Kaldor, I., Ray, J., Samano, V., Furfine, E., Spaltenstein, A., Hale, M., Tung, R., St. Clair, M., Hanlon, M., Boone, L. (2007). In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV. Antimicrob. Agents Chemother. 51: 3147-3154 [Abstract] [Full Text]  
  • Pires, I. L., Soares, M. A., Speranza, F. A. B., Ishii, S. K., Vieira, M. C. G., Gouvea, M. I. F. S., Guimaraes, M. A. A. M., de Oliveira, F. E., Magnanini, M. M. F., Brindeiro, R. M., Tanuri, A. (2004). Prevalence of Human Immunodeficiency Virus Drug Resistance Mutations and Subtypes in Drug-Naive, Infected Individuals in the Army Health Service of Rio de Janeiro, Brazil. J. Clin. Microbiol. 42: 426-430 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dumans, A. T.
Right arrow Articles by Tanuri, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dumans, A. T.
Right arrow Articles by Tanuri, A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»